×
  • Select the area you would like to search.
  • ACTIVE INVESTIGATIONS Search for current projects using the investigator's name, institution, or keywords.
  • EXPERTS KNOWLEDGE BASE Enter keywords to search a list of questions and answers received and processed by the ADNI team.
  • ADNI PDFS Search any ADNI publication pdf by author, keyword, or PMID. Use an asterisk only to view all pdfs.

ADNI 3

ADNI3 began in 2016 and includes scientists at 59 research centers in the United States and Canada. Between 1070-2000 participants will be enrolled: approximately 700-800 rollover participants from ADNI2 and 370-1200 newly enrolled subjects. Clinical, cognitive, imaging, biomarker and genetic characteristics will be assessed across three cohorts: Cognitively normal, MCI and mild AD dementia.

ADNI3: What’s New

In addition to all the biomarkers used in ADNI 2, ADNI 3 has the following changes and additions:

  1. ADNI 3 includes longitudinal tau PET scans with AV 1451 provided by AVID. The study also includes the development of tau PET as a surrogate outcome measure for AD clinical trials.
  2. For new ADNI 3 subjects, we will be using Florbetaben provided by Piramal for amyloid PET.
  3. CSF amyloid and tau will be measured using a new immunoassay platform provided by Roche to determine how tau tangles are related to amyloid levels and to cognition.
  4. MRI techniques from the Human Connectome Project will be used to map the effects of AD on brain connectivity. Protocols will be updated including 3D ASL perfusion imaging and Connectome sequences for appropriate scanners.
  5. Use of high-powered MRI to detect very early structural brain changes in AD.
  6. For the clinical battery, the Financial Capacity Instrument has been added and subjects will take Cogstate computerized testing in-clinic and at home and subjects will be invited to join the Brain Health Registry for at-home assessment. The Brain Health Registry also supports recruitment activities.
  7. Use of Systems Biology approaches to understand AD genetics and its relationship to AD biology.
  8. Development of models to select patients for AD clinical trials using Precision medicine
Cohort Size

 

 

Rollover participants New participants
Cognitively normal (CN) cohort 295-330 135-500
Mild cognitive impairment (MCI) cohort 275-320 150-515
Mild Alzheimer’s disease dementia (AD) cohort 130-150 85-185

 

DOCUMENTS

The full list of ADNI documents can be found on the Documents page. New documents for ADNI 3 can be seen by clicking the links below. Study data and additional password-protected documents can be found in the Image and Data Archive, with instructions for access on the Access Data page.

Standardized MRI Data Sets

In order to promote consistency in data analysis, standardized MRI imaging datasets have been developed for the acquired 1.5T and 3T scans. Researchers are encouraged to use these complete datasets in their analyses and to reference them in reporting results. Doing so will help support direct comparisons of various analysis methods. Details about the rationale and development of the standardized MRI datasets may be found in the document linked below.

Manuals and Schedules

Procedures Manual

For manuals and study schedules, please visit the Documents page. For details on methods and protocols, please visit the Methods & Tools section. Study data and additional password-protected documents can be found in the Image and Data Archive, with instructions for access on the Access Data page. Additional information can be found in the Help/FAQ section.

MRI Scanner Protocols
ADNI-3 Basic and Advanced

There is a broad gulf between older MRI systems and the state of the art production systems within each vendor’s product line. The range of scanners being qualified for use in ADNI scanning as of late 2016 is given in the Scanner Table. A two-tiered approach is taken to accommodate the range of variability in scanners. Thus, “ADNI-3 Basic” and “ADNI-3 Advanced” protocols have been created. An underlying assumption is that scanners will be upgraded replaced over the lifespan of ADNI-3 leading to increased use of the ADNI-3 Advanced protocols. Structural T1-weighted, 3D FLAIR, T2* GRE, ASL, and high resolution images of the hippocampus are common across basic and advanced protocols within each vendor. The Advanced Diffusion MRI and Resting State fMRI scans take advantage of simultaneous multislice acceleration for echo-planar images (EPI). For longitudinal consistency, they can be down-sampled postscan to match the Basic sequences. See details in the link below.

ADNI 3 MRI Protocols Quick Guide

General Electric (GE) Healthcare Philips Medical Systems Siemens Medical Solutions
GE 25x
GE Widebore 25x
Philips R3
Philips R5
Siemens 20VB17
Siemens Prisma D13
Siemens Skyra E11
Siemens Prisma VE11C

 

Further Reading